Cardio Diagnostics (CDIO)

• Market cap: $5.42M
• 1 day: 1.1%
• 5 days: -6.15%
• 1 month: -9.85%
• 3 months: 36.57%
• 6 months: -52.59%
• Year to date: -35.56%
• 1 year: -71.27%
• 5 years: -99.38%
• 10 years: -99.38%
• Sector: Healthcare
• Industry: Biotechnology

About: Cardio Diagnostics Holdings Inc is a medical technology company focused on developing and commercializing epigenetics-based clinical tests for cardiovascular diseases and associated comorbidities by leveraging its Artificial Intelligence (AI)-driven Multi-Omics Engine. The company has developed two clinical products: Epi+Gen CHD and PrecisionCHD, epigenetics-based clinical blood tests capable of assessing risk for a coronary heart disease (CHD) event, including heart attacks. Additionally, its portfolio includes HeartRisk, a cardiovascular disease risk intelligence platform, and CardioInnovate360, a research-use-only solution launched to support the discovery, development, and validation of novel biopharmaceuticals for the assessment and management of cardiovascular diseases.

Employees: 17